Usefulness of KIT mutant transcript levels for monitoring measurable residual disease in t (8;21) acute myeloid leukemia

被引：3

作者：

Sun, Yuan ^{[1
,2
]}

Wang, Xu ^{[1
]}

Chen, Wen-Min ^{[1
]}

Hao, Yue ^{[1
]}

Li, Ling-Di ^{[1
]}

Li, Jin-Ying ^{[1
]}

Sun, Kai ^{[1
]}

Shi, Zong-Yan ^{[1
]}

Jiang, Hao ^{[1
]}

Jiang, Qian ^{[1
]}

Huang, Xiao-Jun ^{[1
]}

Qin, Ya-Zhen ^{[1
,3
]}

机构：

[1] Peking Univ, Inst Hematol, Natl Clin Res Ctr Hematol Dis, Peoples Hosp,Beijing Key Lab Hematopoiet Stem Cell, Beijing, Peoples R China

[2] Beijing Hightrust Diagnost Co Ltd, Beijing, Peoples R China

[3] 11 Xizhimen South St, Beijing, Peoples R China

来源：

HEMATOLOGICAL ONCOLOGY | 2024年 / 42卷 / 02期

基金：

中国国家自然科学基金;

关键词：

digital PCR; KIT mutant transcript levels; measurable residual disease; relapse; t (8; 21) AML; MESSENGER-RNA; RISK STRATIFICATION; AML; EXPRESSION; MUTATIONS; PCR; RELAPSE; ALLOWS;

D O I：

10.1002/hon.3264

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

In addition to RUNX1::RUNX1T1 transcript levels, measurable residual disease monitoring using KIT mutant (KITmut) DNA level is reportedly predictive of relapse in t (8; 21) acute myeloid leukemia (AML). However, the usefulness of KITmut transcript levels remains unknown. A total of 202 bone marrow samples collected at diagnosis and during treatment from 52 t (8; 21) AML patients with KITmut (D816V/H/Y or N822K) were tested for KITmut transcript levels using digital polymerase chain reaction. The individual optimal cutoff values of KITmut were identified by performing receiver operating characteristics curve analysis for relapse at each of the following time points: at diagnosis, after achieving complete remission (CR), and after Course 1 and 2 consolidations. The cutoff values were used to divide the patients into the KITmut-high (KIT_H) group and the KITmut-low (KIT_L) group. The KIT_H patients showed significantly lower relapse-free survival (RFS) and overall survival (OS) rates than the KIT_L patients after Course 1 consolidation (p = 0.0040 and 0.021, respectively) and Course 2 consolidation (p = 0.018 and 0.011, respectively) but not at diagnosis and CR. The <3-log reduction in the RUNX1::RUNX1T1 transcript levels after Course 2 consolidation was an independent adverse prognostic factor for RFS and OS. After Course 2 consolidation, the KIT_H patients with >3-log reduction in the RUNX1::RUNX1T1 transcript levels (11/45; 24.4%) had similar RFS as that of patients with <3-log reduction in the RUNX1::RUNX1T1 transcript levels. The combination of KITmut and RUNX1::RUNX1T1 transcript levels after Course 2 consolidation may improve risk stratification in t (8; 21) AML patient with KIT mutation.

引用

页数：11

共 24 条

[1] KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis [J].

Arock, M. ;

Sotlar, K. ;

Akin, C. ;

Broesby-Olsen, S. ;

Hoermann, G. ;

Escribano, L. ;

Kristensen, T. K. ;

Kluin-Nelemans, H. C. ;

Hermine, O. ;

Dubreuil, P. ;

Sperr, W. R. ;

Hartmann, K. ;

Gotlib, J. ;

Cross, N. C. P. ;

Haferlach, T. ;

Garcia-Montero, A. ;

Orfao, A. ;

Schwaab, J. ;

Triggiani, M. ;

Horny, H-P ;

Metcalfe, D. D. ;

Reiter, A. ;

Valent, P. .

LEUKEMIA, 2015, 29 (06) :1223-1232

[2] Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia:: results from Cancer and Leukemia Group B (CALGB 8461) [J].

Byrd, JC ;

Mrózek, K ;

Dodge, RK ;

Carroll, AJ ;

Edwards, CG ;

Arthur, DC ;

Pettenati, MJ ;

Patil, SR ;

Rao, KW ;

Watson, MS ;

Koduru, PRK ;

Moore, JO ;

Stone, RM ;

Mayer, RJ ;

Feldman, EJ ;

Davey, FR ;

Schiffer, CA ;

Larson, RA ;

Bloomfield, CD .

BLOOD, 2002, 100 (13) :4325-4336

[3] Determination of minimal residual disease in leukaemia patients [J].

Campana, D .

BRITISH JOURNAL OF HAEMATOLOGY, 2003, 121 (06) :823-838

[4] Digital Droplet PCR Is a Reliable Tool to Improve Minimal Residual Disease Stratification in Adult Philadelphia-Negative Acute Lymphoblastic Leukemia [J].

Della Starza, Irene ;

De Novi, Lucia A. ;

Santoro, Alessandra ;

Salemi, Domenico ;

Spinelli, Orietta ;

Tosi, Manuela ;

Soscia, Roberta ;

Paoloni, Francesca ;

V. Cappelli, Luca V. ;

Cavalli, Marzia ;

Apicella, Valerio ;

Bellomarino, Vittorio ;

Di Lello, Eleonora ;

Vitale, Antonella ;

Vignetti, Marco ;

Fabbiano, Francesco ;

Rambaldi, Alessandro ;

Bassan, Renato ;

Guarini, Anna ;

Chiaretti, Sabina ;

Foa, Robin .

JOURNAL OF MOLECULAR DIAGNOSTICS, 2022, 24 (08) :893-900

[5] Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN [J].

Doehner, Hartmut ;

Wei, Andrew H. ;

Appelbaum, Frederick R. ;

Craddock, Charles ;

DiNardo, Courtney D. ;

Dombret, Herve ;

Ebert, Benjamin L. ;

Fenaux, Pierre ;

Godley, Lucy A. ;

Hasserjian, Robert P. ;

Larson, Richard A. ;

Levine, Ross L. ;

Miyazaki, Yasushi ;

Niederwieser, Dietger ;

Ossenkoppele, Gert ;

Roellig, Christoph ;

Sierra, Jorge ;

Stein, Eytan M. ;

Tallman, Martin S. ;

Tien, Hwei-Fang ;

Wang, Jianxiang ;

Wierzbowska, Agnieszka ;

Lowenberg, Bob .

BLOOD, 2022, 140 (12) :1345-1377

[6] Mutually exclusive mutations of KIT and RAS are associated with KIT mRNA expression and chromosomal instability in primary intracranial pure germinomas [J].

Fukushima, Shintaro ;

Otsuka, Ayaka ;

Suzuki, Tomonari ;

Yanagisawa, Takaaki ;

Mishima, Kazuhiko ;

Mukasa, Akitake ;

Saito, Nobuhito ;

Kumabe, Toshihiro ;

Kanamori, Masayuki ;

Tominaga, Teiji ;

Narita, Yoshitaka ;

Shibui, Soichiro ;

Kato, Mamoru ;

Shibata, Tatsuhiro ;

Matsutani, Masao ;

Nishikawa, Ryo ;

Ichimura, Koichi .

ACTA NEUROPATHOLOGICA, 2014, 127 (06) :911-925

[7] Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations [J].

Gorello, P. ;

Cazzaniga, G. ;

Alberti, F. ;

Dell'Oro, M. G. ;

Gottardi, E. ;

Specchia, G. ;

Roti, G. ;

Rosati, R. ;

Martelli, M. F. ;

Diverio, D. ;

Lo Coco, F. ;

Biondi, A. ;

Saglio, G. ;

Mecucci, C. ;

Falini, B. .

LEUKEMIA, 2006, 20 (06) :1103-1108

[8] C-kit mRNA expression in pancreatic adenocarcinoma and matched stromal tissue: Prognostic and therapeutic implications [J].

Grimminger, Peter Philipp ;

Stephens, Craig ;

Waldschmidt, Dirk ;

Astrow, Stephanie H. ;

Steffen, Hans-Michael ;

Hsiang, Jack ;

Zeger, Gary ;

Hoelscher, Arnulf H. ;

Maus, Marlin K. H. .

JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)

[9] Prognostic value of real-time quantitative PCR (RQ-PCR) in AML with t(8;21) [J].

Leroy, H ;

de Botton, S ;

Grardel-Duflos, N ;

Darre, S ;

Leleu, X ;

Roumier, C ;

Morschhauser, F ;

Lai, JL ;

Bauters, F ;

Fenaux, P ;

Preudhomme, C .

LEUKEMIA, 2005, 19 (03) :367-372

[10] Clinical significance of droplet digital PCR quantitative monitoring of KIT gene mutation levels in core binding factor leukemia [J].

Liu, Zhuang ;

Wang, Wenjun ;

Zheng, Chaofeng ;

Tan, Yanhong ;

Chen, Xiuhua ;

Xu, Jing ;

Xu, Zhifang ;

Ren, Fanggang ;

Zhang, Yaofang ;

Li, Guoxia ;

Chang, Jianmei ;

Wang, Hongwei .

INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2018, 40 (06) :E124-E126

← 1 2 3 →